Understanding Ketamine's Dissociative Effects (KD Study)
NCT ID: NCT04861051
Last Updated: 2024-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
20 participants
INTERVENTIONAL
2021-07-26
2028-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
NCT02216500
Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
NCT00556387
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
NCT03633058
RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00564915
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
NCT00205712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketamine
Study participants will receive 0.5mg/kg of ketamine - one single infusion
Ketamine
Study participants will receive 0.5mg/kg of ketamine - one single infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine
Study participants will receive 0.5mg/kg of ketamine - one single infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years old.
Exclusion Criteria
* Inability to speak, read or understand English
* Pregnant or nursing females
* Prior adverse ketamine response
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karl Deisseroth
Professor of Bioengineering and of Psychiatry and Behavioral Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karl Deisseroth, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University School of Medicine
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Karl Deisseroth, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
60085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.